David Hirsch - 23 Jul 2021 Form 4 Insider Report for Poseida Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 23 Jul 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 26 Jul 2021, 20:30:30 UTC
Prior SEC filing: 20 Jul 2021
Next SEC filing: 10 Jun 2022
Source filing: View source filing
Reporting owner signature: /s/ Harry J. Leonhardt, Attorney-in-Fact

Key filing fact

David Hirsch filed Form 4 for Poseida Therapeutics, Inc. on 26 Jul 2021.

Key facts

This page summarizes David Hirsch's Form 4 filing for Poseida Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 26 Jul 2021, 20:30.

Change

Previous filing in this sequence was filed on 20 Jul 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PSTX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +25,833
Change %
Price: $0.000000
Shares after: 25,833
Date: 23 Jul 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,833
Exercise price: $8.63
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock option will vest and become exercisable on the earlier to occur of (i) June 16, 2022 and (ii) the day preceding the date of the 2022 annual meeting of the Issuer's stockholders.